Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus

Vaccine

Volumn 28, Issue 4, 2010, Pages 1075-1083

  Whiteman, Melissa C ^a,d   Li, Li ^a   Wicker, Jason A ^a   Kinney, Richard M ^b   Huang, Claire ^b   Beasley, David W C ^a   Chung, Kyung Min ^c   Diamond, Michael S ^c   Solomon, Tom ^d   Barrett, Alan D T ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Attenuation; Glycosylation; West Nile virus

Indexed keywords

NONSTRUCTURAL PROTEIN 1; VIRUS ENVELOPE PROTEIN; WEST NILE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DEGLYCOSYLATION; FEMALE; GLYCOSYLATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIREMIA; VIRUS INFECTION; VIRUS MUTANT; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; GLYCOSYLATION; MICE; PLAQUE ASSAY; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIREMIA; VIRULENCE; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 74249090620     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.112     Document Type: Article

References (51)

1. Lanciotti R.S., Roehrig J.T., Deubel V., Smith J., Parker M., Steele K., et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286 December (5448) (1999) 2333-2337
2. Hayes E.B., and Gubler D.J. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 57 (2006) 181-194
3. Hayes E.B., Sejvar J.J., Zaki S.R., Lanciotti R.S., Bode A.V., and Campbell G.L. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 11 August (8) (2005) 1174-1179
4. Beasley D.W., and Barrett A.D. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76 December (24) (2002) 13097-13100
5. Butrapet S., Kimura-Kuroda J., Zhou D.S., and Yasui K. Neutralizing mechanism of a monoclonal antibody against Japanese encephalitis virus glycoprotein E. Am J Trop Med Hyg 58 April (4) (1998) 389-398
6. Khromykh A.A., Sedlak P.L., and Westaway E.G. trans-Complementation analysis of the flavivirus Kunjin ns5 gene reveals an essential role for translation of its N-terminal half in RNA replication. J Virol 73 November (11) (1999) 9247-9255
7. Maier C.C., Delagrave S., Zhang Z.X., Brown N., Monath T.P., Pugachev K.V., et al. A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology 362 June (2) (2007) 468-474
8. Tan T.T., Bhuvanakantham R., Li J., Howe J., and Ng M.L. Tyrosine 78 of premembrane protein is essential for assembly of West Nile virus. J Gen Virol 90 May (Pt 5) (2009) 1081-1092
9. Liu W.J., Wang X.J., Clark D.C., Lobigs M., Hall R.A., and Khromykh A.A. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol 80 March (5) (2006) 2396-2404
10. Munoz-Jordan J.L., Sanchez-Burgos G.G., Laurent-Rolle M., and Garcia-Sastre A. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 100 November (24) (2003) 14333-14338
11. Miller S., Kastner S., Krijnse-Locker J., Buhler S., and Bartenschlager R. The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J Biol Chem 282 March (12) (2007) 8873-8882
12. Roosendaal J., Westaway E.G., Khromykh A., and Mackenzie J.M. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. J Virol 80 May (9) (2006) 4623-4632
13. Alcon-LePoder S., Sivard P., Drouet M.T., Talarmin A., Rice C., and Flamand M. Secretion of flaviviral non-structural protein NS1: from diagnosis to pathogenesis. Novartis Found Symp 277 (2006) 233-247 discussion 47-53
14. Diamond M.S., Pierson T.C., and Fremont D.H. The structural immunology of antibody protection against West Nile virus. Immunol Rev 225 October (2008) 212-225
15. Wong S.J., Boyle R.H., Demarest V.L., Woodmansee A.N., Kramer L.D., Li H., et al. Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J Clin Microbiol 41 September (9) (2003) 4217-4223
16. Schlesinger J.J., Foltzer M., and Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192 January (1) (1993) 132-141
17. Bakonyi T., Gould E.A., Kolodziejek J., Weissenbock H., and Nowotny N. Complete genome analysis and molecular characterization of Usutu virus that emerged in Austria in 2001: comparison with the South African strain SAAR-1776 and other flaviviruses. Virology 328 October (2) (2004) 301-310
18. Blitvich B.J., Scanlon D., Shiell B.J., Mackenzie J.S., Pham K., and Hall R.A. Determination of the intramolecular disulfide bond arrangement and biochemical identification of the glycosylation sites of the nonstructural protein NS1 of Murray Valley encephalitis virus. J Gen Virol 82 September (Pt 9) (2001) 2251-2256
19. Chambers T.J., McCourt D.W., and Rice C.M. Production of yellow fever virus proteins in infected cells: identification of discrete polyprotein species and analysis of cleavage kinetics using region-specific polyclonal antisera. Virology 177 July (1) (1990) 159-174
20. Sumiyoshi H., Mori C., Fuke I., Morita K., Kuhara S., Kondou J., et al. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 161 December (2) (1987) 497-510
21. Dalgarno L., Trent D.W., Strauss J.H., and Rice C.M. Partial nucleotide sequence of the Murray Valley encephalitis virus genome. Comparison of the encoded polypeptides with yellow fever virus structural and non-structural proteins. J Mol Biol 187 February (3) (1986) 309-323
22. Flamand M., Deubel V., and Girard M. Expression and secretion of Japanese encephalitis virus nonstructural protein NS1 by insect cells using a recombinant baculovirus. Virology 191 December (2) (1992) 826-836
23. Pryor M.J., and Wright P.J. Glycosylation mutants of dengue virus NS1 protein. J Gen Virol 75 May (Pt 5) (1994) 1183-1187
24. Beasley D.W., Whiteman M.C., Zhang S., Huang C.Y., Schneider B.S., Smith D.R., et al. Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol 79 July (13) (2005) 8339-8347
25. Kinney R.M., Huang C.Y., Whiteman M.C., Bowen R.A., Langevin S.A., Miller B.R., et al. Avian virulence and thermostable replication of the North American strain of West Nile virus. J Gen Virol 87 December (Pt 12) (2006) 3611-3622
26. Hanna S.L., Pierson T.C., Sanchez M.D., Ahmed A.A., Murtadha M.M., and Doms R.W. N-linked glycosylation of west Nile virus envelope proteins influences particle assembly and infectivity. J Virol 79 November (21) (2005) 13262-13274
27. Crabtree M.B., Kinney R.M., and Miller B.R. Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses. Arch Virol 150 April (4) (2005) 771-786
28. Muylaert I.R., Chambers T.J., Galler R., and Rice C.M. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. Virology 222 August (1) (1996) 159-168
29. Pletnev A.G., Bray M., and Lai C.J. Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J Virol 67 August (8) (1993) 4956-4963
30. Pryor M.J., Gualano R.C., Lin B., Davidson A.D., and Wright P.J. Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins. J Gen Virol 79 November (Pt 11) (1998) 2631-2639
31. Chung K.M., Nybakken G.E., Thompson B.S., Engle M.J., Marri A., Fremont D.H., et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 80 February (3) (2006) 1340-1351
32. Blitvich B.J., Mackenzie J.S., Coelen R.J., Howard M.J., and Hall R.A. A novel complex formed between the flavivirus E and NS1 proteins: analysis of its structure and function. Arch Virol 140 1 (1995) 145-156
33. Winkler G., Randolph V.B., Cleaves G.R., Ryan T.E., and Stollar V. Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer. Virology 162 January (1) (1988) 187-196
34. Blitvich B.J., Scanlon D., Shiell B.J., Mackenzie J.S., and Hall R.A. Identification and analysis of truncated and elongated species of the flavivirus NS1 protein. Virus Res 60 March (1) (1999) 67-79
35. Mason P.W. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells. Virology 169 April (2) (1989) 354-364
36. Monath T.P. Pathobiology of flaviviruses. In: Schlesinger S.S.a.M.J. (Ed). The Togaviridae and Flaviviridae (1986), Plenum Press, New York 375-440
37. Monath T.P., Arroyo J., Levenbook I., Zhang Z.X., Catalan J., Draper K., et al. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol 76 February (4) (2002) 1932-1943
38. Kramer L.D., Li J., and Shi P.Y. West Nile virus. Lancet Neurol 6 February (2) (2007) 171-181
39. Vanlandingham D.L., McGee C.E., Klingler K.A., Galbraith S.E., Barrett A.D., and Higgs S. Short report: comparison of oral infectious dose of West Nile virus isolates representing three distinct genotypes in Culex quinquefasciatus. Am J Trop Med Hyg 79 December (6) (2008) 951-954
40. Hall R.A., and Khromykh A.A. West Nile virus vaccines. Expert Opin Biol Ther 4 August (8) (2004) 1295-1305
41. Huang C.Y., Silengo S.J., Whiteman M.C., and Kinney R.M. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J Virol 79 June (12) (2005) 7300-7310
42. Pugachev K.V., Guirakhoo F., and Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 18 October (5) (2005) 387-394
43. Ledizet M., Kar K., Foellmer H.G., Wang T., Bushmich S.L., Anderson J.F., et al. A recombinant envelope protein vaccine against West Nile virus. Vaccine 23 June (30) (2005) 3915-3924
44. Schalich J., Allison S.L., Stiasny K., Mandl C.W., Kunz C., and Heinz F.X. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J Virol 70 July (7) (1996) 4549-4557
45. Yamshchikov G., Borisevich V., Seregin A., Chaporgina E., Mishina M., Mishin V., et al. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology 330 December (1) (2004) 304-312
46. Yu L., Robert Putnak J., Pletnev A.G., and Markoff L. Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations. Vaccine 26 November (47) (2008) 5981-5988
47. Hall R.A., Brand T.N., Lobigs M., Sangster M.Y., Howard M.J., and Mackenzie J.S. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice. J Gen Virol 77 June (Pt 6) (1996) 1287-1294
48. Kreil T.R., Maier E., Fraiss S., and Eibl M.M. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J Virol 72 April (4) (1998) 3076-3081
49. Mota J., Acosta M., Argotte R., Figueroa R., Mendez A., and Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23 May (26) (2005) 3469-3476
50. Thullier P., Demangel C., Bedouelle H., Megret F., Jouan A., Deubel V., et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82 August (Pt 8) (2001) 1885-1892
51. Volpina O.M., Volkova T.D., Koroev D.O., Ivanov V.T., Ozherelkov S.V., Khoretonenko M.V., et al. A synthetic peptide based on the NS1 non-structural protein of tick-borne encephalitis virus induces a protective immune response against fatal encephalitis in an experimental animal model. Virus Res 112 September (1-2) (2005) 95-99